Latest Period
Q1 2026
Security Snapshot
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) Institutional Ownership
CUSIP: 004890109
13F Institutional Holders and Ownership History from Q4 2022 to Q1 2026
Institutions Reporting
42
Shares (Excl. Options)
16,219,592
Price
$1.39
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Symbol
- ACRV on Nasdaq
- Shares outstanding
- 42,655,924
- Price per share
- $1.90
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 16,219,592
- Total reported value
- $22,544,669
- % of total 13F portfolios
- 0%
- Share change
- -2,508,483
- Value change
- -$6,157,656
- Number of holders
- 42
- Price from insider filings
- $1.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 004890109.
- 42 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 48 to 42 between Q4 2025 and Q1 2026.
- Reported value moved from $44,851,327 to $22,544,669.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 42 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 004890109:
Significant Owners of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 29% | +33% | $15,847,529 | +$5,016,666 | 12,284,906 | +46% | RA Capital Management, L.P. | 22 Apr 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.8% | $2,525,900 | 2,122,605 | Sands Capital Life Sciences Pulse Fund II, L.P. | 30 Jun 2025 |
As of 31 Mar 2026, 42 institutional investors reported holding 16,219,592 shares of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV). This represents 38% of the company’s total 42,655,924 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20% | 8,340,508 | 0% | 0.12% | $11,593,306 |
| Sands Capital Alternatives, LLC | 5% | 2,122,605 | 0% | 0.7% | $2,950,421 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.1% | 888,130 | 0% | 0% | $1,234,501 |
| ACADIAN ASSET MANAGEMENT LLC | 2% | 845,973 | +46% | 0% | $1,175,000 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 758,440 | +20% | 0% | $1,054,232 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 722,035 | 0% | 0% | $1,003,629 |
| MARSHALL WACE, LLP | 1.3% | 560,436 | +13% | 0% | $779,007 |
| TWO SIGMA INVESTMENTS, LP | 0.91% | 389,395 | -33% | 0% | $541,259 |
| JANE STREET GROUP, LLC | 0.56% | 239,691 | -30% | 0% | $333,171 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.55% | 236,391 | +19% | 0% | $328,689 |
| BlackRock, Inc. | 0.49% | 208,939 | +1.9% | 0% | $290,425 |
| GSA CAPITAL PARTNERS LLP | 0.44% | 186,716 | 0.02% | $260,000 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.37% | 158,900 | +270% | 0% | $220,871 |
| VANGUARD FIDUCIARY TRUST CO | 0.25% | 107,529 | 0% | 0% | $149,465 |
| STATE STREET CORP | 0.16% | 67,145 | 0% | 0% | $93,332 |
| XTX Topco Ltd | 0.16% | 66,882 | +225% | 0% | $92,966 |
| NORTHERN TRUST CORP | 0.11% | 48,902 | -23% | 0% | $67,973 |
| MORGAN STANLEY | 0.09% | 36,671 | -22% | 0% | $50,973 |
| UBS Group AG | 0.08% | 34,634 | -90% | 0% | $48,141 |
| PANAGORA ASSET MANAGEMENT INC | 0.08% | 33,814 | 0% | $47,001 | |
| Squarepoint Ops LLC | 0.06% | 27,472 | +5% | 0% | $38,186 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.06% | 24,015 | -50% | 0% | $33,381 |
| Marex Group plc | 0.05% | 20,000 | +100% | 0% | $27,800 |
| DIMENSIONAL FUND ADVISORS LP | 0.04% | 18,364 | 0% | 0% | $25,356 |
| GOLDMAN SACHS GROUP INC | 0.03% | 14,742 | -88% | 0% | $20,491 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 16,219,592 | $22,544,669 | -$6,157,656 | $1.39 | 42 |
| 2025 Q4 | 18,610,735 | $44,851,327 | +$2,731,349 | $2.41 | 48 |
| 2025 Q3 | 17,461,169 | $31,603,874 | -$171,329 | $1.81 | 45 |
| 2025 Q2 | 17,802,633 | $21,184,501 | -$10,332,852 | $1.19 | 52 |
| 2025 Q1 | 22,517,048 | $45,710,668 | -$2,113,900 | $2.03 | 60 |
| 2024 Q4 | 23,250,351 | $139,966,100 | -$971,335 | $6.02 | 60 |
| 2024 Q3 | 22,960,755 | $160,726,039 | -$2,679,680 | $7.00 | 51 |
| 2024 Q2 | 23,451,873 | $136,019,583 | +$47,352,617 | $5.80 | 51 |
| 2024 Q1 | 15,245,438 | $109,005,559 | +$3,386,877 | $7.15 | 45 |
| 2023 Q4 | 14,865,624 | $73,138,289 | +$986,082 | $4.92 | 40 |
| 2023 Q3 | 15,093,861 | $144,297,342 | -$326,020 | $9.56 | 43 |
| 2023 Q2 | 15,126,531 | $196,038,750 | -$1,147,208 | $12.96 | 40 |
| 2023 Q1 | 15,216,182 | $191,059,725 | +$6,824,894 | $12.69 | 39 |
| 2022 Q4 | 14,965,637 | $170,360,092 | +$170,360,092 | $11.52 | 18 |